Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1731P - Molecular diagnostics for cancer patients and high-risk individuals during the SARS-CoV-2 pandemic at the Institute for Oncology and Radiology of Serbia

Date

17 Sep 2020

Session

E-Poster Display

Topics

COVID-19 and Cancer

Tumour Site

Presenters

Milena Cavic

Citation

Annals of Oncology (2020) 31 (suppl_4): S934-S973. 10.1016/annonc/annonc289

Authors

M. Cavic1, A. Krivokuca2, A. Damjanovic-Velickovic1, M. Pavlovic1, M. Mihajlovic1, J. Rakobradovic1, I. Boljevic1, E. Malisic1, M. Tanic1, R. Jankovic1

Author affiliations

  • 1 Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 - Belgrade/RS
  • 2 Genetic Counseling For Hereditary Cancers, Institute for Oncology and Radiology of Serbia, 11000 - Belgrade/RS

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1731P

Background

The SARS-CoV-2 pandemic introduced a dangerous distraction effect in all aspects of oncological patients’ care. The aim of this research was to explore the effect of the pandemic on the efficacy of the largest molecular diagnostics centre for cancer patients and high-risk individuals in Serbia (IORS).

Methods

EGFR, KRAS, BRAF, BRCA1/2 mutation testing of advanced lung adenocarcinoma, metastatic colorectal, metastatic melanoma and ovarian cancer patients were performed by qPCR and NGS. NGS was also used for panel testing of hereditary breast cancer and cancers associated with Lynch syndrome. IORS's analytical output during the two-month long state of emergency was compared to the two-month period prior to the outbreak.

Results

A 57% reduction (188 vs. 81) in the total number of patients that were referred to IORS for targeted molecular testing was detected (EGFR - prior to initiation of TKI therapy 55 vs 26 patients, at progression 21 vs 4; KRAS 73 vs 34, BRAF 39 vs. 17). Due to the prolonged transport of the necessary consumables and the fact that two essential laboratory personnel were absent from the Institute (sensitive category and obligatory quarantine), somatic testing for BRCA1/2 mutations was not performed at all during the state of emergency. All new high-risk individuals with the referral for genetic counselling had to be postponed, so the lockdown was used to test the patients who were waiting for results. The number of NGS analyses for high-risk individuals increased by 50 % during the outbreak (36 vs. 72) and post-test genetic counselling was successfully performed by phone and/or web calls.

Conclusions

The SARS-CoV-2 pandemic had a profound negative effect on the overall diagnostic output of the centralized molecular diagnostics for cancer patients and high-risk individuals in Serbia. This effect will be further evaluated through the analysis of both the survival and quality of life of the cancer patients that were unable to receive targeted therapies in a timely efficient manner. The only positive effect of the pandemic was that the waiting lists for genetic testing of high-risk individuals were shortened.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Ministry of Education and Science of the Republic of Serbia.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.